1. Ngondi JL, et al. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids in Health and Disease. 2009; 8, article 7.
2. Méndez-Del Villar M, et al. Effect of Irvingia gabonensis on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion. J Med Food. 2018 Jun; 21(6): 568–574.
3. Tomiyama AJ. Low Calorie Dieting Increases Cortisol. Psychosom Med. 2010 May; 72(4): 357–364.
4. Mann T, et al. The search for effective obesity treatments: Should Medicare fund diets? American Psychologist. 2007; 62: 220–233.
5. Peos JJ, et al. Intermittent Dieting: Theoretical Considerations for the Athlete. Sports (Basel). 2019; 7(1): 22.
6. Johanssen DL, et al. Metabolic slowing with massive weight loss despite preservation of fat-free mass. J Clin Endocrinol Metab. 2012; 97: 2489–2496.
7. Fothergill E, et al. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity 2016; 24(8): 1612–1619.
8. Ludwig DS, Ebbeling CB. The carbohydrate-insulin model of obesity: beyond “Calories In, Calories Out”. JAMA Intern Med 2018; 178: 1098–1103.
9. Samaha FF, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348: 2074–2081.
10. High Cholesterol Facts | cdc.gov 2022.
11. 국민건강영양조사 2020년
12. Caleyachetty R, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2021; 9: 419–426.
13. Kashima, S, et al. Prevalence and characteristics of non-obese diabetes in Japanese men and women: The Yuport Medical Checkup Center Study. J. Diabetes 2015; 7: 523–530.
14. Yang HK, et al. Obesity, metabolic health, and mortality in adults: a nationwide
15. Chen GC, et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J. 2019; 40: 2849–2855.
16. Eckel N, et al. Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis. Eur. J. Prev. Cardiol. 2016; 23: 956–966.
17. Ziyi Zhou, et al. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. Diabetologia. 2021; 64: 1963–1972.
18. Stunkard A, et al. An adoption study of human obesity. NEJM. 1986; 314: 193–198.
19. Bray GA. Contemporary diagnosis and management of obesity. Newtown, PA: Handbooks in Health Care, 1998.
20. McQuaid SE, et al. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes. 2011; 60: 47–55.
21. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58: 773–795.
22. Lee SH, et al. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J 2022; 46(1): 15–37.
23. Tabák AG, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009; 373: 2215–2221.
24. Pearson, T, et al. The Effects of Insulin Resistance on Individual Tissues: An Application of a Mathematical Model of Metabolism in Humans. Bull Math Biol 2016; 78: 1189–1217.
25. Chen Y, Lee Y, Tsao Y, et al Association between high-fasting insulin levels and metabolic syndrome in non-diabetic middle-aged and elderly populations: a community-based study in Taiwan. BMJ Open 2018; 8:e016554. Doi: 10.1136/bmjopen-2017-016554.
26. Sung, KC.C., Seo, MH.H., Rhee, EJ.J. et al. Elevated fasting insulin predicts the future incidence of metabolic syndrome: a 5-year follow-up study. Cardiovasc Diabetol 10, 108 (2011). https://doi.org/10.1186/1475-2840-10-108
27. Jeong J, Suh YJ. Association between Serum Uric Acid and Metabolic Syndrome in Koreans. J Korean Med Sci. 2019 Dec; 34(48): e307.
28. Tanabe A, Tatsumi F, Okauchi S, et al. Optimal cut-off value of alanine aminotransferase level to precisely estimate the presence of fatty liver in patients with poorly controlled type 2 diabetes. J Diabetes Investig 2016; 7: 645–646.
29. Arner P, et al. Human white adipose tissue: A highly dynamic metabolic organ. Journal of Internal Medicine. 2022; 291(5): 611–621.
30. Spalding KL, et al. Dynamics of fat cell turnover in humans. Nature. 2008; 453: 783–787.
31. Longo M. et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications Int J Mol Sci. 2019; 20(9): 2358.
32. Lloyd LJ, et al. Childhood obesity and adult cardiovascular disease risk: a systematic review. International Journal of Obesity. 2010; 34: 18–28.
33. Wrzosek M, et al. Early Onset of Obesity and Adult Onset of Obesity as Factors Affecting Patient Characteristics Prior to Bariatric Surgery. Obes Surg. 2018; 28(12): 3902–3909.
34. Wang X, et al. Adipose Tissue Aging and Metabolic Disorder, and the Impact of Nutritional Interventions. Nutrients. 2022; 14(15): 3134.
35. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434–438.
36. Vos MB, et al. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008; 10: 160.
37. Maruhama Y, Macdonald I. Incorporation of orally administered glucose-U-14C and fructose-U-14C into the triglyceride of liver, plasma, and adipose tissue of rats. Metabolism. 1973; 22(9): 1205–1215.
38. Geidl-Flueck B, et al. Fructose and sucrose but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. J. Hepatol. 2021; 75: 46–54.
39. Stanhope KL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Investig. 2009; 119: 1322–1334.
40. Lanaspa MA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and independent fatty liver. J Biol Chem. 2012; 287(48): 40732–40744.
41. Ouyang X, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6): 993–999.
42. Maersk M, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012; 95(2): 283–289.
43. Schwarz JM, et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017; 153(3): 743–752.
44. Jensen T. et al. Fructose and Sugar: A Major Mediator of Nonalcoholic Fatty Liver Disease. J Hepatol. J Hepatol. 2018; 68(5): 1063–1075.
45. Wenting Wang, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study. Scientific Reports. 2022; 12: 10 977.
46. Wei H, et al. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study. BMJ Open. 2016; 6.
47. Ruohui Xu a, et al. Recent advances in lean NAFLD. Biomedicine & Pharmacotherapy. 153 (2022) 113331: 1–8.
48. Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73: 202–209.
49. Hart CL, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340.
50. Alkerwi A, et al. Alcohol consumption and the prevalence of metabolic syndrome: a meta-analysis of observational studies. Atherosclerosis. 2009; 204(2): 624–635.
51. Naveau S, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997; 25(1): 108–111.
52. Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc. 2010; 110: 1307–1321.
53. Liu CF, et al. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta- analysis of prospective cohort studies. Int J Clin Pract. 2012; 66: 692–698.
54. Kwak J, et al. Serum γ-glutamyltransferase level and incidence risk of metabolic syndrome in community dwelling adults: longitudinal findings over 12 years. Diabetol Metab Syndr. 2023; 15(1): 29.
55. Thamer C, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res. 2005; 37: 246–251.
56. Voulgari C, et al. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J Am Coll Cardiol. 2011; 58: 1343–1350.
57. Shapiro A, et al. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1370–5.
58. Neel JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum Genet 1962; 14: 353–362.
59. Kim TN, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab. 2013; 20: 1–10.
60. Feraco A, et al. Exploring the Role of Skeletal Muscle in Insulin Resistance: Lessons from Cultured Cells to Animal Models. Int J Mol Sci. 2021; 22: 9327.
61. Kim KS, et al. Association of self-reported sedentary time with insulin resistance among Korean adults without diabetes mellitus: a cross-sectional study. BMC Public Health. 2018; 18(1): 1335.
62. Mattson MP, Wan R. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. J Nutr Biochem. 2005; 16(3): 129–137.
63. Cioffi I, et al. Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials. J Transl Med. 2018; 16(1): 371.
64. Gabel K. et al. Differential Effects of Alternate-Day Fasting Versus Daily Calorie Restriction on Insulin Resistance. Obesity 2019; 27(9): 1443–1450.
65. Jaime TJ. et al. Effect of calorie restriction on energy expenditure in overweight and obese adult women. Nutr Hosp. 2015; 31(6): 2428–2436.
66. Webber J, Macdonald IA. The cardiovascular, metabolic and hormonal changes
67. Zauner C. et al. Resting energy expenditure in short-term starvation is increased as a result of an increase in serum norepinephrine. Am J Clin Nutr. 2000 Jun; 71(6): 1511–1515.
68. Stekovic S, et al. Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans. Cell Metab. 2019 Sep 3; 30(3): 462–476.
69. Hartman ML, et al. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J. Clin. Endocrinol. Metab. 1992; 74: 757–765.
70. Cai H, et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. BMC Gastroenterol. 2019; 19: 219.
71. Holmer M, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial. JHEP Rep. 2021; 3 (100 256): 1–8.
72. Lavallee CM, et al. The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. Nutrients. 2022; 14: (4655): 1–13.
73. Trepanowski JF, et al. Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults: A Randomized Clinical Trial. JAMA Intern Med. 2017; 177(7): 930–938.
74. Liu D, et al. Calorie Restriction with or without Time-Restricted Eating in Weight Loss. N Engl J Med. 2022; 386(16): 1495–1504.
75. Moro, T, et al. Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males. J Transl Med 2016; 14: 290.
76. Khalafi M, et al. Effect of resistance training with and without caloric restriction on visceral fat: A systemic review and meta-analysis. Obes Rev. 2021; 22(9): e13275.
77. Church, TS., et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes. JAMA 2010; 304: 2253–2262.
78. Whyte LJ, et al. Effect of 2 weeks of sprint interval training on health-related outcomes in sedentary overweight/obese men. Metabolism Clinical and Experimental. 2010; 59(10): 1421–1428.
79. Morris JN, Raffle PA. Coronary heart disease in transport workers; a progress report. Br J Ind Med. 1954 Oct;11(4):260-4.
80. Koster A, et al. Association of sedentary time with mortality independent of moderate to vigorous physical activity. PloS One. 2012; 7 (6): e37696.
81. Cooper, AJM., et al. Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes. Diabetologia 2014; 57: 73–82.
82. Peddie MC, et al. Breaking prolonged sitting reduces postprandial glycemia in healthy, normal-weight adults: a randomized crossover trial. Am J Clin Nutr. 2013 Aug; 98(2): 358–366.
83. Duvivier, BMFM., et al. Breaking sitting with light activities vs structured exercise: A randomised crossover study demonstrating benefits for glycaemic control and insulin sensitivity in type 2 diabetes. Diabetologia 2017; 60: 490–498.
84. Buckley JP, et al. Standing-based office work shows encouraging signs of attenuating post-prandial glycaemic excursion. Occup Environ Med. 2014 Feb; 71(2): 109–111.
85. Falck RS, et al. What is the association between sedentary behaviour and cognitive function? A systematic review. Br J Sports Med. 2017; 51(10): 800–811.
86. Gill S., Panda S. Diurnal Eating Patterns in Humans that Can Be Modulated for Health Benefits. Cell metabolism 2015; 22(5): 789–798.
87. Spaeth, AM., et al. Phenotypic vulnerability of energy balance responses to sleep loss in healthy adults. Sci. Rep. 2015; 5: 14 920.
88. Bromley, LE, et al. Sleep restriction decreases the physical activity of adults at risk for type 2 diabetes. Sleep 2012; 35: 977–984.
89. Kootte, R.S.; Levin, E.; Salojarvi, J.; Smits, L.P.; Hartstra, A.V.; Udayappan, S.D.; Hermes, G.; Bouter, K.E.; Koopen, A.M.; Holst, J.J.; et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017; 26: 611–619e616.
90. Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020; 72: 558–577.
91. Ji Y, Yin Y, Li Z, Zhang W. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). Nutrients. (2019) 11: 1712.
92. Fianchi F, et al. Nonalcoholic fatty liver disease (Nafld) as model of gut-liver axis interaction: from pathophysiology to potential target of treatment for personalized therapy. Int J Mol Sci. 2021; 22: 6485.
93. Weintraub M, et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther. 1992; 51(5): 586–594.
94. Connolly HM, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581–588.
95. Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 2001; 384: 989.
96. Unick JL, et al. Look AHEAD Research Group. Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later. Obesity (Silver Spring). 2015 Jul; 23(7): 1353–1356.
97. Moore DR et al. Am J Clin Nutr. 2009; 89: 161.
98. Moore et al. J Gerontol A Biol Sci Med Sci. 2015; 70(1): 57–62.
99. Areta JL, et al. Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. J Physiol. 2013; 591(9): 2319–2331.
100. Fukuhara et al. Effect of cooked rice with β-glucan enriched barley on postprandial glucose response and its second-meal effect. Japanese Pharmacology and Therapeutics. 2013; 41(8): 789–795.
101. Liu K, et al. Can Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels?: The Coronary Artery Risk Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc. 2015; 4(9): e002275.
102. Rodriguez-Segade S, at al. Continuous glucose monitoring is more sensitive than HbA1c and fasting glucose in detecting dysglycaemia in a Spanish population without diabetes. Diabetes Res Clin Pract. 2018; 142: 100–109.
103. Oh TJ, Lim S, Kim KM, Moon JH, Choi SH, Cho YM, Park KS, Jang H, Cho NH. One hour postload plasma glucose concentration in people with normal glucose homeostasis predicts future diabetes mellitus: a 12-year commuity-based cohort study. Clin Endocrinol. 2017; 86(4): 513–519.
104. Peddinti G, Bergman M, Tuomi T, Groop LJ. 1-Hour Post-OGTT Glucose Improves the Early Prediction of Type 2 Diabetes by Clinical and Metabolic Markers. Clin Endocrinol Metab. 2019; 104(4): 1131–1140.
105. Reynolds AN, et al. Advice to walk after meals is more effective for lowering postprandial glycaemia in type 2 diabetes mellitus than advice that does not specify timing: a randomised crossover study. Diabetologia. 2016; 59(12): 2572–2578.